Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 8/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429181 | 0.91 | CREBBP (0.61) | CREBBPMCHR1TRPV1HDAC1HDAC6 | |
| SCHEMBL4435905 | 0.91 | CREBBP (0.60) | CREBBPMCHR1TRPV1HDAC1HDAC6 | |
| SCHEMBL4433775 | 0.90 | CREBBP (0.62) | CREBBPMCHR1TRPV1HDAC1HDAC6 | |
| SCHEMBL4435517 | 0.89 | CREBBP (0.65) | CREBBPMCHR1TRPV1HDAC1HDAC6 | |
| SCHEMBL13930018 | 0.88 | CREBBP (0.67) | CREBBPMCHR1TRPV1HDAC1HDAC6 | |
| SCHEMBL13929832 | 0.88 | CREBBP (0.59) | CREBBPMCHR1TRPV1HDAC1HDAC6 | |
| SCHEMBL4432756 | 0.87 | CREBBP (0.63) | CREBBPMCHR1TRPV1HDAC1HDAC6 | |
| SCHEMBL4435521 | 0.85 | CREBBP (0.60) | CREBBPMCHR1TRPV1HDAC1HDAC6 | |
| SCHEMBL4430220 | 0.84 | AVPR2 (0.61) | CREBBPMCHR1TRPV1HDAC1HDAC6 | |
| SCHEMBL4434512 | 0.84 | CREBBP (0.73) | CREBBPTRPV1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-1480954-B1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-12-03 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | CREBBP 1594/4885MCHR1 266/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.